VolitionRX Ltd
VNRX0.628USD
-0.012-1.88%
Market hours （ET）Quotes delayed by 15 min
63.27MMarket Cap
LossP/E TTM
More Details of VolitionRX Ltd Company
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Company Info
Ticker SymbolVNRX
Company nameVolitionRX Ltd
IPO dateFeb 06, 2015
CEODr. Jasmine Kway
Number of employees85
Security typeOrdinary Share
Fiscal year-endFeb 06
Address1489 West Warm Springs Road
CityHENDERSON
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code89014
Phone17024251561
Websitehttps://volition.com/
Ticker SymbolVNRX
IPO dateFeb 06, 2015
CEODr. Jasmine Kway
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
2.81M
+0.72%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.08M
+10.62%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
456.18K
-4.51%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
362.01K
+38.17%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
313.51K
-1.40%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
203.55K
-10.28%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
191.11K
+4.56%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
159.47K
+0.29%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
144.80K
-3.61%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
138.29K
-2.17%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
2.81M
+0.72%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.08M
+10.62%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
456.18K
-4.51%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
362.01K
+38.17%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
313.51K
-1.40%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
203.55K
-10.28%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 5
Updated: Sat, Jul 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cotterford Co., Ltd.
11.65%
Lagoda Investment Management, L.P.
9.89%
Armistice Capital LLC
7.97%
Innes (Guy Archibald)
2.72%
Reynolds (Cameron John)
2.02%
Other
65.74%
Shareholders
Shareholders
Proportion
Cotterford Co., Ltd.
11.65%
Lagoda Investment Management, L.P.
9.89%
Armistice Capital LLC
7.97%
Innes (Guy Archibald)
2.72%
Reynolds (Cameron John)
2.02%
Other
65.74%
Shareholder Types
Shareholders
Proportion
Corporation
12.63%
Investment Advisor
11.32%
Hedge Fund
8.01%
Individual Investor
7.32%
Investment Advisor/Hedge Fund
1.09%
Research Firm
0.04%
Venture Capital
0.03%
Other
59.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
78
41.39M
40.17%
+893.35K
2025Q1
83
44.42M
46.85%
+2.70M
2024Q4
82
41.53M
44.82%
+1.50M
2024Q3
82
38.59M
41.90%
+9.42M
2024Q2
82
28.77M
32.86%
+105.49K
2024Q1
84
28.22M
34.52%
+1.47M
2023Q4
87
26.17M
37.10%
+183.39K
2023Q3
91
25.37M
36.48%
-477.38K
2023Q2
98
25.03M
37.36%
-1.92M
2023Q1
127
25.94M
45.68%
-639.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cotterford Co., Ltd.
12.01M
11.65%
--
--
Apr 25, 2025
Lagoda Investment Management, L.P.
10.19M
9.89%
+2.62M
+34.56%
Mar 31, 2025
Armistice Capital LLC
8.21M
7.97%
-275.46K
-3.25%
Mar 31, 2025
Innes (Guy Archibald)
2.81M
2.72%
+20.00K
+0.72%
Jun 03, 2025
Reynolds (Cameron John)
1.88M
1.83%
+12.50K
+0.67%
Jun 12, 2025
Concord International Inc.
1.01M
0.98%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
761.95K
0.74%
+18.11K
+2.43%
Mar 31, 2025
The Vanguard Group, Inc.
706.06K
0.69%
+69.39K
+10.90%
Mar 31, 2025
Micallef (Jacob Vincent)
456.18K
0.44%
-21.53K
-4.51%
Jun 01, 2025
BlackRock Institutional Trust Company, N.A.
445.19K
0.43%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
